🟢 Tiziana Life Sciences is trading 10% up today after BTIG initiated coverage with a Buy rating

Tiziana Life Sciences is trading at $1.02 (+10.04%) after BTIG initiated coverage with a Buy rating and $7.00 price target.

• BTIG highlighted intranasal foralumab’s potential in multiple sclerosis and other neurodegenerative diseases.
• BTIG identified the INFORM-MS presentation at the October 2026 ACTRIMS/ECTRIMS meeting as the company’s biggest upcoming catalyst.
• Shares declined from $1.11 on August 25 to $0.93 on September 2, amplifying the reaction.